GELTEQ PTY LTD Aktie

Gelteq has opened a regional competence center in China’s Guangdong province to support product development, formulation and testing capabilities, and several development programs. The company is developing an oral ingestible gel platform for improved drug formulation and says its presence in China will increase development and commercialization speed and operational scalability. Headquartered in Melbourne, Gelteq recorded revenue growth of 188% in the past twelve months, remains unprofitable with a market capitalization of USD 5.2 million, appears to be burning cash quickly, and its stock is down 71% year to date. » Plus sur de.investing.com

Gelteq has entered into a convertible bond agreement with an institutional investor for up to $3.5 million. The first tranche of $1.0 million has already been paid as a convertible bond carrying 7% p.a. interest and an 18‑month term; conversion is possible after six months. The conversion price is 93% of the lowest VWAP of the five trading days prior to the valuation date, with a minimum of $0.50. The investor may, on defined trigger events, increase the outstanding amount up to three times by either 15% or 5%; subsequent defaults allow immediate demand for repayment with 15% interest. A second tranche of $2.5 million (less a discount) is subject to shareholder approval and the absence of trigger events and would carry similar terms. » Plus sur de.investing.com

Gelteq received a notice from Nasdaq that the closing price of its common stock was below $1.00 for 30 consecutive trading days, thereby violating the minimum requirement. Immediate delisting will not occur; the company has until September 14, 2026 (180 days) to regain compliance. If the price reaches $1.00 or more for at least ten consecutive trading days, Nasdaq will confirm compliance; alternatively, if other listing standards are met, an additional extension may be available, for example after a reverse stock split. » Plus sur de.investing.com